Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines

A Trkola, PL Moore - The Lancet Infectious Diseases, 2024 - thelancet.com
Globally, the number of new HIV infections remains unacceptably high, and urgent new
approaches are needed to advance HIV vaccine science. However, the development of a …

Ethics of HIV cure research: an unfinished agenda

K Dubé, J Kanazawa, J Taylor, L Dee, N Jones… - BMC medical …, 2021 - Springer
Background The pursuit of a cure for HIV is a high priority for researchers, funding agencies,
governments and people living with HIV (PLWH). To date, over 250 biomedical studies …

Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption

S Pereira Ribeiro, Z Strongin, H Soudeyns… - Nature …, 2024 - nature.com
Human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) is
associated with heightened plasma interleukin-10 (IL-10) levels and PD-1 expression. We …

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on‐going viral transcription

P Pannus, S Rutsaert, S De Wit… - Journal of the …, 2020 - Wiley Online Library
Introduction Viral remission after analytical treatment interruption (ATI), termed post‐
treatment control, has been described in a small proportion of HIV‐positive patients. This …

The effect of HIV treatment interruption on subsequent immunological response

C Thomadakis, CT Yiannoutsos… - American Journal of …, 2023 - academic.oup.com
Recovery of CD4-positive T lymphocyte count after initiation of antiretroviral therapy (ART)
has been thoroughly examined among people with human immunodeficiency virus infection …

Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies

JSY Lau, MZ Smith, B Allan, C Martinez… - AIDS research and …, 2020 - liebertpub.com
Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused
interventions, but poses potential risks. Understanding of ATI acceptability among people …

[HTML][HTML] Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport

Y Chu, A Wong, H Chen, L Ji, C Qin, W Feng… - European Journal of …, 2023 - Elsevier
The establishment of latent cellular and anatomical viral reservoirs is a major obstacle to
achieving a cure for people infected by HIV. Mesenteric lymph nodes (MLNs) are one of the …

Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy

MC Sneller, ED Huiting, KE Clarridge… - The Journal of …, 2020 - academic.oup.com
Historical data regarding time to viral rebound following analytical treatment interruption
(ATI) have been used to determine therapeutic efficacy in HIV cure trials; however, such data …

CD8 effector T cells function synergistically with broadly neutralizing antibodies to enhance suppression of HIV infection

RT Veenhuis, CC Garliss, JR Bailey… - Frontiers in …, 2021 - frontiersin.org
HIV-specific CD8 T cells and broadly neutralizing antibodies (bNAbs) both contribute to the
control of viremia, but in most cases, neither can completely suppress viral replication. To …

Antiretroviral therapy interruption (ATI) in HIV-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response

L Leal, C Fehér, V Richart, B Torres, F García - Vaccines, 2020 - mdpi.com
A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative
to antiretroviral treatment for life, and therapeutic vaccines represent one of the most …